Ann: AVITA Medical Announces FDA Approval of RECELL GO, page-33

Yep, FY24 is the calendar year in the US.

I wouldn't say that I'm "expecting" them to double sales from $26M in 1H24 to $52.5M in 2H24 in order to reach the $78.5M in commercial revenue. Seems impossible, I know! However, I've done some analysis (for the lack of a better word) based on what we've been told and made some assumptions that provides an achievable line of sight to the $78.5M and the profitability goal. I'd say that I'm not ruling two these expectations out yet - I'm possibly even cautiously optimistic at this stage now that GO has been approved.

As you've highlighted, FY23 revenue growth was around 46% and even though Q124 was flat, with RECELL GO, I think there's a good chance that they can at least match that yoy growth in FY24.

All the best with your future research. There's a lot of good info at https://ir.avitamedical.com/ if you're interested.